Federated Hermes
TARA icon

Federated Hermes’s Protara Therapeutics TARA Stock Holding History

Federated Hermes’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-124
Closed -$332 – 2254
2022
Q4 		$332 Sell
124
-122
-50% -$385 ﹤0.01% 2108
2022
Q3 		$1K Sell
246
-134
-35% -$454 ﹤0.01% 2082
2022
Q2 		$1K Sell
380
-46
-11% -$168 ﹤0.01% 2082
2022
Q1 		$2K Buy
426
+296
+228% +$1.56K ﹤0.01% 2036
2021
Q4 		$1K Buy
+130
New +$896 ﹤0.01% 2153

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PFMU
Privium Fund Management (UK) London, United Kingdom $197M AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Federated Hermes's TARA Position: Q1 2023 in Review

Federated Hermes sold out of Protara Therapeutics (TARA) in Q1 2023, closing a stake of 124 shares — an estimated $332 sold.

Federated Hermes first reported a position in TARA in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q1 2022. 29 funds tracked by Wall St. Rank hold TARA as of Q1 2023.

  • Federated Hermes reported no remaining Protara Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 124 Protara Therapeutics shares in Q1 2023, an estimated $332.
  • Federated Hermes first reported a position in Protara Therapeutics in Q4 2021 and held it in 5 quarters.
  • Federated Hermes's Protara Therapeutics position peaked at $2K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.